Annalisa Curcio

Dr. Annalisa Curcio

Aqma Italia S.p.A.
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2007 in Journal of Biomedical Materials Research Part A
Verified
Journal Article
Closed access
PDF file
MRmaria grazia rimoli
maria grazia rimoli
MRMaria R. Rabaioli
Maria R. Rabaioli
DMDaniela Melisi
Daniela Melisi
Annalisa CurcioAnnalisa Curcio
Annalisa Curcio
SMSandro Mondello
Sandro Mondello
EAEnrico Abignente
Enrico Abignente

28 October 2011 in Nanoscale
Verified
Journal Article
Closed access
PDF file
MMMaria Ada Malvindi
Maria Ada Malvindi
RCRiccardo Di Corato
Riccardo Di Corato
Annalisa CurcioAnnalisa Curcio
Annalisa Curcio
DMDaniela Melisi
Daniela Melisi
MRmaria grazia rimoli
maria grazia rimoli
Andrea RagusaAndrea Ragusa
Andrea Ragusa
The development of fluorescent biolabels for specific targeting and controlled drug release is of paramount importance in biological applications due to their potential in the generation of novel tools for simultaneous diagnosis and treatment of diseases. Dopamine is a neurotransmitter involved in several neurological diseases, such as Parkinson's disease and attention deficit hyperactivity disorder (ADHD), and the controlled delivery of its agonists already proved to have beneficial effects both in vitro and in vivo. Here, we report the synthesis and multiple functionalization of highly fluorescent CdSe/CdS quantum rods for specific biolabeling and controlled drug release. After being transferred into aqueous media, the nanocrystals were made highly biocompatible through PEG conjugation and covered by a carbohydrate shell, which allowed specific GLUT-1 recognition. Controlled attachment of dopamine through an ester bond also allowed hydrolysis by esterases, yielding a smart nanotool for specific biolabeling and controlled drug release.

1 September 2011 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
DMDaniela Melisi
Daniela Melisi
Annalisa CurcioAnnalisa Curcio
Annalisa Curcio
ELElvira Luongo
Elvira Luongo
EMElena Morelli
Elena Morelli
MRmaria grazia rimoli
maria grazia rimoli
D-galactose is a simple and natural compound that has mainly been exploited in prodrug strategies. Galactosyl prodrugs can be considered a good approach to reach different goals in clinical drug application, especially when traditional drugs are likely to fail therapeutically owing to reasons such as the lack of site specificity, toxicity, and chemical instability. Indeed, of paramount importance is their ability to increase the selectivity of the parent compound, a phenomenon that helps to reduce the incidence of adverse effects, while preserving intact the pharmacodynamic features of the parent drug. Study results have varied according to the type of linkage between the drug and the hydroxyl group exploited. By working with these parameters, researchers have been able not only to generate selective pharmacological targeting of brain, liver, and cancerous cells, but also to improve cellular permeability as well as the pharmacokinetic profile of parent drugs. This review describes the broad spectrum of possibilities for exploiting D-galactose as a vector for prodrug design and the synthetic strategies that allow its realization.

17 October 2020 in Medicina
Verified
Journal Article
Open access
PDF file
Annalisa CurcioAnnalisa Curcio
Annalisa Curcio
ARAdriana Romano
Adriana Romano
SCSimona Cuozzo
Simona Cuozzo
ANAntonio Di Nicola
Antonio Di Nicola
OGOrazio Grassi
Orazio Grassi
MPMichele Pironti
Michele Pironti
Background and Objectives: Non-Alcoholic Fatty Liver Disease (NAFLD) is an emerging cause of hepatopathy that is showing an increasing trend and where the recommendations of lifestyle modification are often not sufficient. The aim of this study is to evaluate the efficacy and tolerability profile of the association of silymarin, vitamin C, vitamin E, coenzyme Q10 and selenomethionine (Medronys epato®) by analyzing liver enzymes, along with the lipidic profile, as markers of liver function, and ultrasound results in NAFLD patients. Materials and Methods: This study enrolled 81 patients with mild to severe NAFLD, divided into two groups: Group A (N = 41) received two capsules a day of silymarin, vitamin C, vitamin E, coenzyme Q10 and selenomethionine (Medronys epato®), and Group B (N = 40) received only recommendations for lifestyle modification including hypocaloric diet, physical exercise and encouragement for weight loss. Patients have been evaluated at three timepoints: baseline (T0), after 45 days of treatment (T1) and after 90 days of treatment (T2), by collecting blood parameters of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT) and the lipid blood profile. Ultrasonographic results have been analyzed at T0 and T2, along with the tolerability profile and side effects, registered at time T2. Results: The administration of the association of silymarin, vitamin C, vitamin E, coenzyme Q10 and selenomethionine (Medronys epato®) was effective since it showed a significant reduction of the evaluated parameters of ALT, AST, ALP and GGT, a significant improvement of lipid parameters, evaluated as markers of liver function, and improvements of ultrasonographic results. The use of this formulation at the dosage of two capsules a day has been well tolerated and no adverse events have been reported during study period of three months. Conclusions: The administration of the association of silymarin, vitamin C, vitamin E, coenzyme Q10 and selenomethionine (Medronys epato®) was effective and well tolerated in the improvement of hepatic function of NAFLD patients.

1 March 2009 in Neuropharmacology
Verified
Journal Article
Closed access
MRmaria grazia rimoli
maria grazia rimoli
EREmilio Russo
Emilio Russo
MCMauro Cataldi
Mauro Cataldi
RCRita Citraro
Rita Citraro
PAPaolo Ambrosino
Paolo Ambrosino
EAEnrico Abignente
Enrico Abignente

21 May 2009 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Annalisa CurcioAnnalisa Curcio
Annalisa Curcio
OSOscar Sasso
Oscar Sasso
DMDaniela Melisi
Daniela Melisi
MNMaria Nieddu
Maria Nieddu
GRGiovanna La Rana
Giovanna La Rana
MRmaria grazia rimoli
maria grazia rimoli